Key result
Intravenous amiodarone was associated with a 1.5% incidence of drug-induced Torsades de Pointes (4 of 268 patients), with no immediate or late mortality observed.
Why the study?
What is the incidence of drug-induced Torsades de Pointes in patients receiving intravenous amiodarone?
Observational (n=268)
What is the incidence of drug-induced Torsades de Pointes in patients receiving intravenous amiodarone?
Intravenous amiodarone is associated with a ~1.5% incidence of drug-induced Torsades de Pointes, which has a favorable prognosis if recognized and treated promptly.
Answers are grounded in this paper and cite their sources.
TdP with IV amiodarone warrants monitoring; leaves open risk predictors and incidence via prospective studies.
AIM: To define the incidence, presentation, and outcomes of drug-induced Torsades de Pointes (TdP) with intravenous (IV) amiodarone. METHODS: From January 2014 to August 2016 a total of 268 patients received IV amiodarone, 142 for ventricular tachycardia, 104 for atrial flutter/fibrillation, and 22 for incessant atrial tachycardia. A uniform dosing of amiodarone to yield 1gm/day was used in all patients. RESULTS: Four of the 268 patients (M:F 1:3) with mean age of 51.25+9.17years developed pause dependent TdP degenerating to VF, after a mean dose of 690+176.63mg, infused over 12+5.88h. The QTc that was 505+9.02ms at the time of TdP normalized to 433.75+6.13ms 48-72h after stopping amiodarone. There was no immediate or late mortality, and patients are well at 5-10 months of follow-up. None of the patients tested positive for LQTS genes. CONCLUSION: The incidence of drug-induced TdP with IV amiodarone is about 1.5%. Risk factors include female sex, left ventricular dysfunction, electrolyte abnormalities, baseline prolonged QTc, concomitant beta-blocker, and digoxin therapy. Amiodarone induced TdP has favorable prognosis if recognized and treated promptly, and these patients should not receive amiodarone by any route in future.
No takes yet. Share an insight, caveat, or question.
Shenthar et al. (2017) conducted an observational in Ventricular tachycardia, atrial flutter/fibrillation, or incessant atrial tachycardia (n=268). Intravenous amiodarone was evaluated on Incidence of drug-induced Torsades de Pointes (TdP). Intravenous amiodarone was associated with a 1.5% incidence of drug-induced Torsades de Pointes (4 of 268 patients), with no immediate or late mortality observed.
Synapse has enriched 10 related papers. Consider them for comparative context: